Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sosei Acquires GPCR Firm Heptares

by Lisa M. Jarvis
March 2, 2015 | A version of this story appeared in Volume 93, Issue 9

Japan’s Sosei Group has agreed to acquire London-based Heptares Therapeutics, a private company that develops small molecules and biologics targeting G protein-coupled receptors. Heptares shareholders score $180 million in cash and could get an additional $220 million in milestone payments. Sosei gains a pipeline of drugs to treat neurological and metabolic diseases and a structure-based drug design platform. Sosei says Heptares will position it for the loss of patent protection on two of its respiratory products marketed by Novartis.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.